Drug Research

Gilead Sciences has expanded its R&D infrastructure with a new 182,000-square-foot facility in Foster City dedicated to inflammation, oncology, and data science.

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

The pharmaceutical industry currently faces a significant challenge regarding the consistency of experimental results, a phenomenon often referred to as the reproducibility crisis. Central to this issue is the variability of biological reagents, particularly antibodies, which are fundamental tools...

Novo Nordisk has announced a strategic partnership with Amazon Web Services (AWS), naming it its preferred cloud provider and strategic AI partner, with the shared goal of accelerating drug discovery and modernising the company's technology infrastructure to prepare for...

Huawei intends to deepen its artificial intelligence partnerships with pharmaceutical companies, according to William Zhang, president of the company's healthcare business unit, who confirmed to Reuters that the firm's current AI drug projects run predominantly with domestic Chinese drugmakers....

Japan-based Chugai Pharmaceutical has entered into an exclusive license agreement with British pharmaceutical company GlaxoSmithKline (GSK) for the anti-dengue virus antibody known as AID351, in a move that advances global efforts to combat one of the world's most widespread...